Adamax vs Semax
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Adamax
Adamax is a modified version of Semax with an adamantane group attached, designed to enhance its nootropic effects and extend duration of action compared to standard Semax.
Full details →Semax
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent.
Full details →Side-by-Side Comparison
| Aspect | Adamax | Semax |
|---|---|---|
| Dose Range | 200 mcg–750 mcg | 300 mcg–600 mcg |
| Frequency | 1x daily | 2x daily |
| Cycle Length | 2–4 weeks | 2–4 weeks |
| Route | intranasal | intranasal |
| Mechanism | Similar to Semax - enhances BDNF expression and modulates dopamine/serotonin systems. The adamantane modification may increase lipophilicity and CNS penetration. | Enhances BDNF expression, modulates dopamine and serotonin systems, and provides neuroprotective effects. Increases attention, memory formation, and learning. |
| Typical Dosage | Intranasal: 100-500mcg 1-2 times daily. Lower doses than standard Semax may be effective due to enhanced potency. | Intranasal: 200-600mcg 2-3 times daily. Higher doses (up to 1mg) used in clinical settings for stroke recovery. |
| Administration | Intranasal spray is most common route. More stable than standard Semax. Often used for acute cognitive enhancement. | Primarily administered intranasally. N-Acetyl Semax Amidate (NASA) is a modified version with enhanced stability and potency. |
| Side Effects | Similar to Semax - possible irritability, hair shedding, or overstimulation. May have stronger effects than standard Semax. | Generally well-tolerated. May cause mild irritability or hair shedding in some users. |
| Best For |
What They Have in Common
Adamax, Semax are both commonly used for:
Which Has Stronger Evidence?
- Cognitive Performance: Semax has stronger research support.
| Goal | Adamax | Semax |
|---|---|---|
| Cognitive Performance | low | high |
Key Studies
Semax
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
British journal of pharmacology, 2025
- The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.
Acta naturae, 2025
- The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons.
Bulletin of experimental biology and medicine, 2025
Ready to Learn More?
Looking for trusted sources?